| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | +20.5% | -40.5% |
| Cost of Revenue | $1.0M | +66.9% | +158.7% |
| R&D Expense | $572K | -9.1% | +24.3% |
| SG&A Expense | $1.5M | +3.1% | +14.1% |
| Operating Income | -$1.9M | -11.4% | -850.3% |
| Net Income | -$2.0M | -10.2% | -871.2% |
| EPS (Basic) | -$0.06 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.8M | +172.5% | -1.5% |
| Short-term Investments | $3.1M | +9.0% | — |
| Accounts Receivable | $917K | +28.1% | +159.7% |
| Current Assets | $11.5M | +55.9% | +8.0% |
| Total Assets | $11.7M | +43.4% | +8.0% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.9M | — | — |
| Investing Cash Flow | -$386K | — | — |
| Financing Cash Flow | $5.0M | — | — |
| +0.0% |
| -500.0% |
| EPS (Diluted) | -$0.06 | +0.0% | -500.0% |
| $4.1M |
| +10.7% |
| +95.1% |
| Total Liabilities | $9.1M | +4.6% | +22.6% |
| Stockholders' Equity | $2.6M | +592.2% | -23.6% |